Remdesivir improves biomarkers associated with disease severity in COVID-19 patients treated in an outpatient setting

BACKGROUND: Remdesivir (RDV) is an intravenous antiviral with activity against SARS-CoV-2 for treatment of hospitalized COVID-19 patients with moderate-to-severe disease. Biomarkers associated with clinical outcomes have been identified for COVID-19, but few evaluated in context of antiviral treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, David Z., Odorizzi, Pamela M., Schoenichen, Andre, Abdelghany, Mazin, Chen, Shuguang, Osinusi, Anu, Patterson, Scott D., Downie, Bryan, Juneja, Kavita, Wallin, Jeffrey J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9809529/
https://www.ncbi.nlm.nih.gov/pubmed/36596885
http://dx.doi.org/10.1038/s43856-022-00232-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9809529/
https://www.ncbi.nlm.nih.gov/pubmed/36596885
http://dx.doi.org/10.1038/s43856-022-00232-2

Ejemplares similares